Q1 2016 13F Holders as of 3/31/2016
-
Type / Class
-
Equity / Class 'A' Ordinary Shares
-
Shares outstanding
-
386M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
17.3M
-
Shares change
-
+19.3K
-
Total reported value, excl. options
-
$201M
-
Value change
-
+$107K
-
Number of buys
-
42
-
Number of sells
-
-30
-
Price
-
$11.66
Significant Holders of Trinity Biotech plc - Class 'A' Ordinary Shares (TRIB) as of Q1 2016
86 filings reported holding TRIB - Trinity Biotech plc - Class 'A' Ordinary Shares as of Q1 2016.
Trinity Biotech plc - Class 'A' Ordinary Shares (TRIB) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.3M shares
of 386M outstanding shares and own 4.48% of the company stock.
Largest 10 shareholders include Boston Partners (1.66M shares), Paradice Investment Management LLC (1.44M shares), JANUS CAPITAL MANAGEMENT LLC (1.41M shares), HEARTLAND ADVISORS INC (1.29M shares), BANK OF MONTREAL /CAN/ (1.01M shares), ACK Asset Management LLC (980K shares), Park West Asset Management LLC (900K shares), ROYCE & ASSOCIATES LP (799K shares), Lapides Asset Management, LLC (705K shares), and Senvest Management, LLC (617K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.